Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EPS (Basic) (2019 - 2026)

Relay Therapeutics has reported EPS (Basic) over the past 6 years, most recently at -$0.31 for Q4 2025.

  • Quarterly EPS (Basic) rose 26.19% to -$0.31 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.61 through Dec 2025, up 31.78% year-over-year, with the annual reading at -$1.61 for FY2025, 31.78% up from the prior year.
  • EPS (Basic) was -$0.31 for Q4 2025 at Relay Therapeutics, up from -$0.43 in the prior quarter.
  • Over five years, EPS (Basic) peaked at -$0.31 in Q4 2025 and troughed at -$2.1 in Q2 2021.
  • The 5-year median for EPS (Basic) is -$0.62 (2024), against an average of -$0.66.
  • The largest YoY upside for EPS (Basic) was 92.15% in 2021 against a maximum downside of 113.72% in 2021.
  • A 5-year view of EPS (Basic) shows it stood at -$0.62 in 2021, then grew by 11.29% to -$0.55 in 2022, then dropped by 21.82% to -$0.67 in 2023, then surged by 37.31% to -$0.42 in 2024, then rose by 26.19% to -$0.31 in 2025.
  • Per Business Quant, the three most recent readings for RLAY's EPS (Basic) are -$0.31 (Q4 2025), -$0.43 (Q3 2025), and -$0.41 (Q2 2025).